Table 3.

Ongoing trials in Merkel cell carcinoma (MCC).

	NCT Identifier	Study Title	Conditions	Phases	Patients
Targeted Therapies	NCT04869137	Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma	MCC	PHASE2	26
	NCT03787602	Navtemadlin (KRT-232) with or without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients with Merkel Cell Carcinoma	MCC	PHASE1/2	115
	NCT02514824	MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma	Recurrent or metastatic MCC	PHASE1|2	9
Immunotherapy	NCT04291885	Immunotherapy Adjuvant Trial in Patients with Stage I-III Merkel Cell Carcinoma	MCC	PHASE2	132
	NCT05496036	Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma	MCC	PHASE2	15
	NCT06151236	Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma	MCC	PHASE2	20
	NCT03599713	A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)	Metastatic MCC	PHASE2	107
	NCT02488759	An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors	Advanced MCC	PHASE1/2	578
	NCT03458117	T-VEC in Non-melanoma Skin Cancer	MCC	PHASE1	26
	NCT02819843	A Study of T-VEC (Talimogene Laherparepvec) with or without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors	MCC	PHASE2	19
	NCT02978625	Talimogene Laherparepvec and Nivolumab in Treating Patients with Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers	MCC	PHASE2	68
	NCT02155647	Avelumab in Participants with Merkel Cell Carcinoma (JAVELIN Merkel 200)	MCC	PHASE2	204
	NCT04393753	Domatinostat in Combination with Avelumab in Patients with Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1	Advanced MCC	PHASE2	19
	NCT05422781	Study to Evaluate The Safety, Tolerability and Immunogenicity of 4 mg of ITI-3000 In Patients with Polyomavirus-Positive Merkel Cell Carcinoma (MCC)	VP-MCC	PHASE1	6